These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39068585)

  • 1. Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma.
    Saad E; Abdelwahed M; Moussa R; Abdulla M
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2499-2507. PubMed ID: 39068585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
    Navarria P; Minniti G; Clerici E; Tomatis S; Pinzi V; Ciammella P; Galaverni M; Amelio D; Scartoni D; Scoccianti S; Krengli M; Masini L; Draghini L; Maranzano E; Borzillo V; Muto P; Ferrarese F; Fariselli L; Livi L; Pasqualetti F; Fiorentino A; Alongi F; di Monale MB; Magrini S; Scorsetti M
    J Neurooncol; 2019 Mar; 142(1):59-67. PubMed ID: 30515706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.
    Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E
    J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
    Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
    J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
    J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
    Klobukowski L; Falkov A; Chelimo C; Fogh SE
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas.
    Song A; Andrews DW; Werner-Wasik M; Kim L; Glass J; Bar-Ad V; Evans JJ; Farrell CJ; Judy KD; Daskalakis C; Zhan T; Shi W
    Radiother Oncol; 2019 Mar; 132():135-141. PubMed ID: 30825962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy.
    Fleischmann DF; Gajdi L; Corradini S; Schönecker S; Marschner S; Bodensohn R; Hofmaier J; Garny S; Forbrig R; Thon N; Belka C; Niyazi M
    Radiother Oncol; 2024 Oct; 199():110437. PubMed ID: 39013502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
    Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
    Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
    Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
    J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial.
    Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J
    J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma.
    Chen ATC; Serante AR; Ayres AS; Tonaki JO; Moreno RA; Shih H; Gattás GS; Lopez RVM; Dos Santos de Jesus GR; de Carvalho IT; Marotta RC; Marta GN; Feher O; Neto HS; Ribeiro ISN; Vasconcelos KGMDC; Figueiredo EG; Weltman E
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(4):1122-1132. PubMed ID: 38232937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis.
    Pinzi V; Orsi C; Marchetti M; Milanesi IM; Bianchi LC; DiMeco F; Cuccarini V; Farinotti M; Ferroli P; Finocchiaro G; Franzini A; Fumagalli M; Silvani A; Fariselli L
    Neurol Sci; 2015 Aug; 36(8):1431-40. PubMed ID: 25805705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.